ST7/LRP12 Antibody [Alexa Fluor® 750]

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 750

ST7/LRP12 Antibody [Alexa Fluor® 750] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human ST7/LRP12
  Asn28-Ile488
  Accession # Q9Y561
• Specificity: Detects human ST7/LRP12 in direct ELISAs and Western blots. In direct ELISAs, 100% cross-reactivity with recombinant mouse ST7/LRP12 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ST7/LRP12 Antibody [Alexa Fluor® 750]

• DKFZp762O2113
• FAM4A1
• LRP12
• Protein FAM4A1
• Protein HELG
• RAY1
• SEN4
• ST7
• subfamily A, member 1
• suppression of tumorigenicity 7 (breast)
• suppression of tumorigenicity 7
• suppressor of tumorigenicity 7 protein
• TSG7

Background

ST7 (Suppressor of Tumorigenicity 7), also known as RAY1, TSG7 and FAM4A1, is a type I transmembrane protein belonging to the LDLR superfamily and is designated LRP12 (1-3). The human ST7 cDNA encodes 859 amino acids (aa) including a 32 aa signal sequence, a 460 aa extracellular domain (ECD) containing two CUB domains and five LDLR class A domains, a 21 aa transmembrane domain, and a 346 aa cytoplasmic domain containing motifs implicated in endocytosis and signal transduction (1, 2). Human ST7 shares 95% aa sequence homology with mouse and rat, 96% with canine, and 98% with bovine, equine and porcine ST7 within the ECD. Genomic sequencing indicates the possibility of up to 18 splicing isoforms, but expression of these has not been well-studied (3). ST7 is widely expressed in normal tissues, especially fibroblasts (1, 4). Highest mRNA levels were detected in heart and skeletal muscle (1). ST7 was originally proposed to be a tumor suppressor protein, but it is not consistently down‑regulated in a variety of cancers, either by mutation or loss of heterozygosity (1, 4-7). In certain cancers, expression may even be up‑regulated (8). Expression may be associated with down‑regulated expression of extracellular matrix molecules that are involved in remodeling, such as SPARC, IGFBP5 and several matrix metalloproteinases, and modulation of in vivo tumorigenicity (4, 5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9Y561()